Top GlaxoSmithKline Government Contracts
GlaxoSmithKline plc is a biopharmaceutical firm that develops, manufactures, and distributes unique medicines and vaccines to diagnose, prevent, and treat disease. GSK has been a reliable US government contractor for many years. Read here to learn the top GlaxoSmithKline government contracts.
-
Table of Contents
Government Purchase of Injectable Influenza Vaccine
Image by BaLL LunLa from Shutterstock.com
- Contracting Activity: Defense Logistics Agency Troop Support
- Contract type: Firm-fixed-price, indefinite-quantity
- Value: $33.8 Million
- Operational site: Pennsylvania, New Jersey
GlaxoSmithKline and Seqirus Inc. received a one-year contract from the Defense Logistics Agency to supply an injectable influenza vaccine, which will be used by the Army, Air Force, Navy, Marine Corps, and Coast Guard. GSK received $33.8 million, while Seqirus Inc. received $8.6 million, all coming from the defense working capital funds from 2022 to 2023 These vaccines are requested to be delivered no later than February 2023.
GSK and Sequirus Inc. have been on joint venture contracts to facilitate the injectable influenza vaccine. Here are some of them:
- On February 23, 2021, GSK received $44.5 million, while Seqirus Inc. received $22.6 million.
- On June 27, 2018, GSK received $27.8 million, while Seqirus Inc. received $27.5 million.
-
DLA Procurement of Influenza Virus Vaccine
Photo by trairut noppakaew from Shutterstock.com
- Contracting Activity: Defense Logistics Agency Troop Support
- Contract type: Firm-fixed-price, indefinite-quantity contract
- Value: $28 Million
GlaxoSmithKline LLC and Seqirus Inc. received another contract from the DLA for the influenza virus vaccine through competitive acquisition. GSK got an estimated $28 million, and Seqirus got an estimated $35 million budget for this contract.
The performances will take place in Pennsylvania, New Jersey, North Carolina, and Germany and will be over on June 22, 2018.
3. DLA Procurement of Multi-Dose Influenza Vaccine Vials
Photo by Joeahead from Shutterstock.com
- Contracting Activity: Defense Logistics Agency Troop Support
- Contract type: Firm-fixed-price, indefinite-quantity contract
- Value: $17 Million
- Operational site: North Carolina
GlaxoSmithKline, Research Triangle Park in North Carolina, received a $17 million contract from the DLA. The contract required GSK to procure multi-dose influenza vaccine vials distributed to the Army, Air Force, Marine Corps, and federal civilian agencies.
GSK got the contract from a competitive acquisition. It has a one-year base period, and work operations concluded before June 2017.
4. U.S. Army Purchase Additional Doses Sotrovimab
Image by Mongkolchon Akesin from Shutterstock.com
- Contracting Activity: U.S. Army Contracting Command
- Contract type: Modification contract
- Value: $945 Million
- Operational site: Durham, North Carolina
The U.S. Army granted GlaxoSmithKline a $945 million deal to purchase an extra 340,048 doses of the therapeutic drug Sotrovimab. The contract has the option to buy an additional 715,680 quantities by June 30, 2022. The work will take place in Durham, North Carolina, until September 30, 2022.
5. GSK to Provide Influenza Vaccine and Prefilled Syringes for the Military Use
Image by Jacob Lund from Shutterstock.com
- Contracting Activity: Defense Logistics Agency Troop Support
- Contract type: Firm-fixed-price, indefinite-quantity contract
- Value: $11.8 Million
- Operational site: North Carolina
After a competitive bidding process, GlaxoSmithKline was awarded a contract for $11.8 million to supply influenza vaccine and prefilled syringes. This contract will benefit the U.S. Army, Navy, U.S. Air Force, U.S. Marine Corps, and federal civilian agencies.
This agreement has a fixed term of one year and no further optional years. The project commenced in North Carolina and concluded in June 2016.
GlaxoSmithKline FAQs
Image by MAXSHOT.PL from Shutterstock
What is GlaxoSmithKline known for?
GSK is well-known for its successful pharmaceuticals, widely-used prescription treatments, and vaccines. The company’s catalog of products ranges from treatments for asthma, lupus, HIV/AIDs, and harmful diseases.
What products does GlaxoSmithKline make?
GlaxoSmithKline plc is a successful firm in the global pharmaceutical and health insurance markets. Here are the three primary products that the company provides.
- Vaccines
GSK vaccinations have been used for decades, preventing potentially deadly illnesses such as whooping cough, polio, and measles from affecting countless individuals. - Specialty medicines
Cancer medicines from GSK save patients’ lives, and this includes treatments for ovarian cancer, endometrial cancer, and multiple myeloma. The company has boosted its study and now offers three cancer medicines on the market in addition to nine assets in development. - General medicines
GSK has been a pioneer in respiratory science, producing medicines that have improved the quality of life for millions of people who suffer from breathing difficulties.
Who owns GlaxoSmithKline?
In August 2019, GlaxoSmithKline combined its brand portfolio with Pfizer creating the world’s largest over-the-counter healthcare company. Following the terms of the deal, GSK will retain 68% of the joint venture, and Pfizer will own the remaining 32%. Together, the two firms will manage the United States and China, the largest OTC markets worldwide.
Where is GlaxoSmithKline’s headquarters?
The US headquarters of GlaxoSmithKline is residing in Philadelphia’s Navy Yard and North Carolina’s Research Triangle Park. The company’s consumer products sector sits in Moon Township, Pennsylvania.
Uniting Science, Technology, and Talent to Combat Diseases
Throughout its history, GlaxoSmithKline PLC has been led by dedicated executives and leaders who have made the company a global giant in the pharmaceutical and biotechnology sectors. GlaxoSmithKline’s R&D department is dedicated to developing cutting-edge immunology, genetics, and technology products to better human health.
Category: Articles
